![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Tag: Coronavirus information (COVID-19)
Clinical Trials
Dr. Reddy’s receives approval to conduct Phase 3 clinical trial for Sputnik V vaccine in India
Dr. Reddy’s Laboratories Ltd announced that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial...
News
COVID-19 vaccine: Bharat Biotech set to dispatch first consignment of Covaxin
Hyderabad, Bharat Biotech, which has received Emergency Use Authorisation approval from theDrug Controller General of Indiafor its COVID-19 vaccine Covaxin, is set to dispatch...
Drug Research
US FDA grants emergency use authorization to Quanterixs Simoa SARS-CoV-2 N protein antigen test
Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, announced that the Food and Drug Administration (FDA) has issued...
Clinical Trials
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI in the I-SPY COVID-19 Trial
NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG, and the Quantum Leap Healthcare Collaborative of San Francisco announce that NeuroRx and QLHC have signed a...
News
AMRI Included in BARDA CDMO Network in Support of COVID-19 Pandemic Response in the U.S.
Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, announced its Albuquerque, New Mexico, facility has...
Clinical Trials
CureVac’s COVID-19 Vaccine Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced the publication of preclinical...
News
Algeria has become the first country in Africa to register Sputnik V vaccine
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the registration of the Russian Sputnik V vaccine against coronavirus by the National...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read